Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 11/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23357299 | 1.00 | OPRD1 (0.58) | OPRD1OPRM1GAAOPRK1EPHX2 | |
| SCHEMBL25152425 | 0.88 | OPRD1 (0.48) | OPRD1OPRM1GAAEPHX2NR1H4 | |
| SCHEMBL23357241 | 0.88 | OPRD1 (0.48) | OPRD1OPRM1GAAOPRK1 | |
| SCHEMBL23357139 | 0.88 | OPRD1 (0.48) | OPRD1OPRM1OPRK1EPHX2NR1H4 | |
| SCHEMBL23357243 | 0.88 | OPRD1 (0.48) | OPRD1OPRM1GAAOPRK1 | |
| SCHEMBL23357137 | 0.88 | OPRD1 (0.48) | OPRD1OPRM1OPRK1EPHX2NR1H4 | |
| SCHEMBL29162430 | 0.85 | OPRM1 (0.47) | OPRD1OPRM1OPRK1 | |
| SCHEMBL25152138 | 0.85 | OPRM1 (0.47) | OPRD1OPRM1OPRK1 | |
| SCHEMBL25152141 | 0.85 | OPRD1 (0.58) | OPRD1OPRM1OPRK1NR1H4MET | |
| SCHEMBL23357101 | 0.84 | OPRD1 (0.62) | OPRD1OPRM1EPHX2NR1H4LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168648-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| CN-112867705-B | Opioid receptor modulators and products and methods related thereto | 埃皮欧黛公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-3774722-B1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-10 | — | — | US | disclosed |
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | EPIODYNE, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | EPIODYNE, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-06-03 | — | — | US | disclosed |
| CN-112867705-A | Opioid receptor modulators and products and methods related thereto | 埃皮欧黛公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20210147343-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210147343-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | OPRD1 4/4885OPRM1 1/4885GAA 4242/4885 |
| US-12168648-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | OPRD1 4/4885OPRM1 1/4885GAA 4242/4885 |
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRM1 1/4885GAA 4043/4885 |
| US-11634396-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | OPRD1 4/4885OPRM1 1/4885GAA 4242/4885 |
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRM1 1/4885GAA 4043/4885 |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | OPRD1 4/4885OPRM1 1/4885GAA 4242/4885 |
| US-20210147343-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRM1 1/4885GAA 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.